LAG3 anticorps (Biotin)

N° du produit ABIN2660995

Cet anticorps anti-LAG3 est un anticorps Rat Monoclonal détectant LAG3 dans IHC, FACS et IF. Adapté pour Souris.

Aperçu rapide pour LAG3 anticorps (Biotin) (ABIN2660995)

Antigène: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp LAG3 est conjugé à/à la Biotin

Application: Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunofluorescence (IF)

Clone: C9B7W

Détail du produit anti-LAG3 anticorps (Biotin)

Purification: The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur LAG3

Antigène: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Autre désignation: CD223

Sujet: CD223, also known as LAG-3, is 70 kD type I transmembrane glycoprotein within the Ig superfamily. It is the gene product of lymphocyte activation gene-3 (Lag3) with structural similarity to CD4. CD223 is expressed on activated T cells and NK cells, as well as T regulatory cells. CD223, like CD4, binds MHC class II molecules, but with higher affinity than CD4. In association with the CD3 complex, CD223 has been shown as a negative regulatory molecule to inhibit TCR-mediated signaling and regulate homeostatic T cell expansion. In contrast to inhibition, CD223 has an activation function to promote immune responses by inducing MHC class II signaling in antigen presenting cells.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints